FEDERAL COURT OF AUSTRALIA
Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2009] FCA 1019
PATENTS – application to amend patent – whether amendments allowable under s 102(1) and s 102(2) of the Patents Act 1990 (Cth) – claimed invention relates to the form of the compound – whether a real and reasonably clear disclosure of the feature of “individual needles” in the patent specification – discretion under s 105 of the Act – whether Court should exercise discretion to refuse amendments – whether full and frank disclosure of reasons for amendment – amendments add new claims but do not delete existing claims
Patents Act 1990 (Cth) ss 40(2), 40(3), 102(1), 102(2), 105
Apotex Pty Ltd v Les Laboratoires Servier (2008) 79 IPR 100
Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty Ltd (1999) 48 IPR 625
Gambro Pty Ltd v Fresenius Medical Care South East Asia Pty Ltd (2000) 49 IPR 321
ICI Chemicals & Polymers Ltd v Lubrizol Corp [1999] AIPC ¶91-521
ICI Chemicals & Polymers Ltd v Lubrizol Corporation Inc (2000) 106 FCR 214
Les Laboratoires Servier v Apotex Inc [2008] EWCA Civ 445
Lockwood Security Products Pty Limited v Doric Products Pty Limited (2004) 217 CLR 274
Novartis AG v Bausch & Lomb (Australia) Pty Ltd (2004) 62 IPR 71
Olin Corporation v Super Cartridge Co Pty Ltd (1977) 180 CLR 236
Oxford Gene Technology Ltd v Affymetrix Inc (No 2) [2001] RPC 310
Palmer v Dunlop Perdriau Rubber Company Limited (1937) 59 CLR 30
Pfizer Inc v Commissioner of Patents (2005) 141 FCR 413
Re Hsiung’s Patent [1992] RPC 497
RGC Mineral Sands Pty Ltd v Wimmera Industrial Minerals Pty Ltd (1998) 89 FCR 458
Smith Kline & French Laboratories Limited v Evans Medical Limited [1989] 1 FSR 561
Vector Corp v Glatt Air Techniques Ltd [2007] RPC 12
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (No 2) (1997) 40 IPR 110
Wimmera Industrial Minerals Pty Ltd v RGC Mineral Sands Ltd (No 3) (1997) AIPC ¶91-366C Bodkin, Patent Law in Australia (Lawbook Co, 2008)
D Bucknell, K Beattie, A Goatcher and H Rofe, Australian Patent Law (LexisNexis Butterworths, 2004)
S Thorley, R Miller, G Burkill and C Birss, Terrell on the Law of Patents (16th ed, Sweet & Maxwell, 2006)APOTEX PTY LTD (ACN 096 916 148) v LES LABORATOIRES SERVIER; LES LABORATOIRES SERVIER and SERVIER LABORATORIES (AUST) PTY LTD (ACN 004 838 500) v APOTEX PTY LTD (ACN 096 916 148), SYMBION PHARMACY SERVICES PTY LTD (ACN 000 875 034), CHEM MART PTY LIMITED (ACN 001 235 374), PHARMACOR LIMITED (ACN 121 020 835), GENEPHARM LIMITED (ARBN 003 854 626) and SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118 594)
NSD 657 of 2008
BENNETT J
11 SEPTEMBER 2009
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 657 of 2008
BETWEEN: APOTEX PTY LTD
(ACN 096 916 148)
ApplicantAND: LES LABORATOIRES SERVIER
RespondentAND BETWEEN: LES…
Keep reading for free
Create a free CaseChat account to read Apotex Pty Ltd v Les Laboratoires Servier (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2009] FCA 1019
- Decision Date
CaseChat Overview and Summary
The court had to decide if the proposed amendments to the patent claims were allowable under sections 102(1) and 102(2) of the Patents Act, which require that amendments must be in substance disclosed in the original specification and fairly based on that disclosure. Additionally, the court needed to exercise its discretion under section 105 of the Act to determine whether the amendments should be allowed, considering factors such as delay, unfair advantage, and other relevant circumstances.
The court found that the proposed amendments were allowable under section 102 as they were in substance disclosed in the specification as filed. The specification contained sufficient details about the α crystalline form of perindopril salt, which was relevant to the claims in question. The court also noted that the amendments were fairly based on the disclosure. Regarding the exercise of discretion under section 105, the court rejected Apotex's arguments about Servier's conduct, finding that Servier had not acted unreasonably and had not sought to gain an unfair advantage. Consequently, the court allowed the amendments.
The final orders of the court were to dismiss the notice of motion filed by Apotex, to require Servier to pay Apotex's costs of the motion, and to stay the payment order until a specified date.
Orders
Orders of the court
1. The notice of motion filed by the respondent on 26 May 2008 be dismissed.
2. The respondent pay the applicant’s costs of the notice of motion.
3. Order 2 be stayed until 12:00pm on 17 September 2009.
Note:
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: BENNETT J
The reference to ‘rapid and efficient filtration and drying’, which is said to result from the ‘homogeneous distribution’ of individual needles about 0.2mm long, links back to the previous statement in the body of the specification that it ‘has been important to be able to synthesise [perindopril] by means of a process that can readily be converted to the industrial scale, especially in a form that allows rapid filtration and drying’ (emphasis added). That form is not simply the α crystalline form of the perindopril salt, but rather, the α crystalline compound in the form of individual needles. In addition, existing claim 7 (claim 8 in the specification as filed) claims a process according to any one of claims 2 to 6, characterised in that the perindopril tert-butylamine salt that is thereby obtained is in the form of readily filterable individual needles. This strengthens the conclusion that there is a real and reasonably clear disclosure of the feature of individual needles and this is relevant to the consideration under s 102(1), where the whole of the specification is to be taken into account. It is not necessary for me to decide whether or not there must be a real and reasonably clear disclosure of individual needles as part of the invention, the approach for which Apotex contends. The specification provides that the α crystalline form of the perindopril salt obtained by the process of the invention is in the form of individual needles. The whole of the specification indicates that the invention is the α crystalline form of the perindopril salt that exists in the form of individual needles, characterised by an X-ray diffraction diagram and obtained through carrying out the process of the invention.“Not in substance disclosed” (s 102(1)) and “fair basis” (s 102(2)(b) and s 40(3)) – grounds 3, 4 and 5 In addition to its primary submission that none of the proposed new claims are in substance disclosed in the specification as filed and are not fairly based, Apotex contends that the same can be said in respect of certain specific claims. In that regard, Apotex raises further specific complaints.Claims 27 and 28 Apotex contends that claims 27 and 28 claim a pharmaceutical composition comprising α crystalline perindopril tert-butylamine according to claim 25 and further limited to particular dosage forms such as tablets and lozenges. It says that the specification as filed does not disclose the particular dosage form as being part of the invention and that claims 27 and 28 are not fairly based. The specification states that formulations are intended for oral administration. Among the pharmaceutical compositions specified are those suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration and each of the forms specified in proposed claim 27. The original claims include claims to pharmaceutical compositions for use in the manufacture of medicaments. Claim 28 is to a pharmaceutical composition according to claim 27 in the form of a tablet. Example 2 is to the formulation for a tablet.